Gilead Sciences' Stribild has received an endorsement from the European Medicines Agency's Committee for Medicinal Products for Human Use as a treatment for HIV-1 infection in previously untreated adults and those with no known mutations related with resistance to any of the three antiretroviral agents in Stribild. The drug, which contains cobicistat, elvitegravir and Truvada, has been approved by the FDA.

Related Summaries